Opinion
Video
Important Clinical Considerations for Patients With Bronchiectasis
Panelists discuss how future bronchiectasis research will focus on precision medicine, identify treatable traits, and expand networks of Centers of Excellence to provide advanced care and clinical trial access for patients.
Clinical Brief: Future Directions in Bronchiectasis Research and Care
Main Discussion Topics
- Current research is moving toward precision treatments for specific bronchiectasis phenotypes.
- Development of bronchiectasis Centers of Excellence is improving care coordination.
- Patient support networks provide additional resources beyond medical care.
Key Points for Physicians
- Ongoing clinical trials are investigating the following:
- DPP1 inhibition and neutrophil cascade modulation
- Type 2 inflammation therapies
- Inhaled anti-inflammatory agents
- CFTR modulators in non–cystic fibrosis (CF) bronchiectasis
- The COPD Foundation has established the following:
- 27 bronchiectasis and nontuberculous mycobacteria (NTM) Centers of Excellence
- 6 clinical associate centers
- Plans to expand to 150-plus centers
- Additional patient resources include the NTM patient support network.
Notable Insights
The field is shifting from simply categorizing bronchiectasis as CF vs non-CF toward more nuanced phenotyping that enables targeted treatment approaches.
Clinical Significance
The establishment of specialized centers and increased research focus on bronchiectasis represents a significant advancement in addressing this previously underrecognized condition.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
